In:
Molecular Biomedicine, Springer Science and Business Media LLC, Vol. 3, No. 1 ( 2022-11-09)
Kurzfassung:
We hypothesize that serum irisin can have additional discriminative potency for heart failure (HF) in individuals with type 2 diabetes mellitus (T2DM). The study group comprised 226 consecutive T2DM patients (153 patients with any HF phenotypes and 30 patients without HF) aged 41 to 65 years. The plasma levels N-terminal brain natriuretic pro-peptide (NT-proBNP) and irisin were detected by ELISA at the baseline of the study. We found that the most appropriate cut-off value of irisin (HF versus non-HF) were 10.4 ng/mL (area under curve [AUC] = 0.96, sensitivity = 81.0%, specificity = 88.0%; P = 0.0001). Cutoff point of NT-proBNP that distinguished patients with HF and without it was 750 pmol/L (AUC = 0.78; sensitivity = 72.7%, specificity 76.5%, p = 0.0001). Using multivariate comparative analysis we established that concentrations of irisin 〈 10.4 ng/mL (odds ration [OR] = 1.30; P = 0.001) and NT-proBNP 〉 750 pmol/mL (OR = 1.17; P = 0.042), left atrial volume index (LAVI) 〉 34 mL/m 2 (OR = 1.06; P = 0.042) independently predicted HF. Irisin being added to NT-proBNP improved predictive modality for HF, whereas combination of NT-proBNP and LAVI 〉 34 mL/m 2 did not. In conclusion, we established that irisin had independent predicted potency for HF in patients with established T2DM.
Materialart:
Online-Ressource
ISSN:
2662-8651
DOI:
10.1186/s43556-022-00096-x
Sprache:
Englisch
Verlag:
Springer Science and Business Media LLC
Publikationsdatum:
2022
ZDB Id:
3033856-6
Permalink